Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced its voluntary delisting from the OTCQB Market, effective July 29, 2024. The decision is attributed to low trading volume and administrative requirements associated with the listing. Poolbeg will maintain its listing on the London Stock Exchange's AIM Market under the ticker 'POLB'. The company reassures that this move will not impact its Ordinary Shares trading on AIM. Additionally, Poolbeg reaffirms its ambition for a future dual listing on a major US exchange, such as Nasdaq, subject to meeting listing requirements at an appropriate time.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) ha annunciato il suo delisting volontario dal mercato OTCQB, che sarà effettivo dal 29 luglio 2024. La decisione è attribuita a bassi volumi di scambio e requisiti amministrativi associati alla quotazione. Poolbeg mantiene la sua quotazione sul mercato AIM della Borsa di Londra con il ticker 'POLB'. L'azienda assicura che questa mossa non influenzerà il trading delle sue Azioni Ordinarie su AIM. Inoltre, Poolbeg ribadisce la sua ambizione per un futuro doppio listaggio su una piattaforma importante negli Stati Uniti, come il Nasdaq, a condizione di soddisfare i requisiti di quotazione in un momento opportuno.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) ha anunciado su deslistado voluntario del mercado OTCQB, efectivo el 29 de julio de 2024. La decisión se atribuye a bajos volúmenes de negociación y requisitos administrativos asociados con la cotización. Poolbeg mantendrá su cotización en el mercado AIM de la Bolsa de Londres bajo el ticker 'POLB'. La compañía asegura que este movimiento no impactará el comercio de sus acciones ordinarias en AIM. Además, Poolbeg reafirma su ambición de un futuro listado dual en un importante intercambio estadounidense, como Nasdaq, sujeto a cumplir con los requisitos de cotización en el momento adecuado.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)는 OTCQB 시장에서의 자발적 상장 폐지를 발표하였으며, 이는 2024년 7월 29일부터 시행됩니다. 이 결정은 낮은 거래량과 상장 관련 관리 요구 사항에 기인하고 있습니다. Poolbeg는 런던증권거래소 AIM 시장에서의 상장을 'POLB'라는 티커를 통해 유지할 것입니다. 회사는 이 조치가 AIM에서의 보통주 거래에 영향을 미치지 않을 것이라고 reassuring합니다. 또한 Poolbeg는 미국 주요 거래소, 예를 들어 Nasdaq에 대한 미래의 이중 상장에 대한 목표를 재확인합니다, 적절한 시점에 상장 요건을 충족하는 것을 조건으로 합니다.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) a annoncé son désengagement volontaire du marché OTCQB, effectif le 29 juillet 2024. Cette décision est attribuée à un faible volume de transactions et à des exigences administratives associées à la cotation. Poolbeg maintiendra sa cotation sur le marché AIM de la Bourse de Londres sous le ticker 'POLB'. La société rassure que cette démarche n'affectera pas la négociation de ses actions ordinaires sur AIM. De plus, Poolbeg réaffirme son ambition d'une future double cotation sur une grande bourse américaine, comme le Nasdaq, sous réserve de satisfaire aux exigences de cotation en temps opportun.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) hat seine freiwillige Delistung vom OTCQB-Markt bekannt gegeben, die am 29. Juli 2024 wirksam wird. Die Entscheidung wird auf niedriges Handelsvolumen und administrative Anforderungen zurückgeführt, die mit der Listung verbunden sind. Poolbeg wird seine Listung am AIM-Markt der Londonder Börse beibehalten unter dem Ticker 'POLB'. Das Unternehmen betont, dass dieser Schritt keine Auswirkungen auf den Handel mit seinen Stammaktien am AIM haben wird. Darüber hinaus bestätigt Poolbeg seinen Ehrgeiz für eine zukünftige duale Listung an einer wichtigen US-Börse, wie z.B. Nasdaq, vorausgesetzt, dass die Listungsanforderungen zu gegebener Zeit erfüllt werden.
- Retention of London Stock Exchange AIM Market listing
- Ambition for future dual listing on a major US exchange like Nasdaq
- Voluntary delisting from OTCQB Market due to low trading volume
- Potential reduced visibility and access for US investors
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares ("Ordinary Shares") from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQB Market will be Monday 29 July 2024.
Poolbeg will retain its listing on the London Stock Exchange's AIM Market under its existing ticker "POLB". The delisting from the OTCQB market will have no impact on Poolbeg's Ordinary Shares, which will continue to trade on the AIM Market.
Poolbeg reaffirms its ambitions to be dual listed on a national securities exchange in the US, such as Nasdaq, subject to meeting their listing requirements at the appropriate time.
Enquiries
Poolbeg Pharma Plc | +44 (0) 207 183 1499 |
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) | +44 (0) 207 220 0500 |
Shore Capital Stockbrokers Ltd (Joint Broker) | +44 (0) 207 408 4090 |
J&E Davy (Joint Broker) | +353 (0) 1 679 6363 |
Optimum Strategic Communications | +44 (0) 208 078 4357 |
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Poolbeg Pharma PLC
View the original press release on accesswire.com
FAQ
When will Poolbeg Pharma (POLBF) delist from the OTCQB Market?
Why is Poolbeg Pharma (POLBF) delisting from the OTCQB Market?
Will Poolbeg Pharma's delisting from OTCQB affect its AIM Market listing?
Does Poolbeg Pharma plan to list on any other US exchanges in the future?
